BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arihiro S, Ohtani H, Suzuki M, Murata M, Ejima C, Oki M, Kinouchi Y, Fukushima K, Sasaki I, Nakamura S. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn’s disease. Pathol Int. 2002;52:367-374. [PMID: 12100519 DOI: 10.1046/j.1440-1827.2002.01365.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 95] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Cho JY, Chi S, Chun HS. Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. Mol Nutr Food Res 2011;55:239-46. [DOI: 10.1002/mnfr.201000070] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
2 Ambruzova Z, Mrazek F, Raida L, Stahelova A, Faber E, Indrak K, Petrek M. Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation. Hum Immunol 2009;70:457-60. [PMID: 19286444 DOI: 10.1016/j.humimm.2009.03.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
3 Chu ZX, Qin HL. Progress of gut associated lymphocyte homing in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2009; 17(7): 687-693 [DOI: 10.11569/wcjd.v17.i7.687] [Reference Citation Analysis]
4 Bachmann C, Klibanov AL, Olson TS, Sonnenschein JR, Rivera–nieves J, Cominelli F, Ley KF, Lindner JR, Pizarro TT. Targeting Mucosal Addressin Cellular Adhesion Molecule (MAdCAM)-1 to Noninvasively Image Experimental Crohn’s Disease. Gastroenterology 2006;130:8-16. [DOI: 10.1053/j.gastro.2005.11.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 4.7] [Reference Citation Analysis]
5 de Krijger M, Wildenberg ME, de Jonge WJ, Ponsioen CY. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. J Hepatol 2019;71:603-15. [PMID: 31108158 DOI: 10.1016/j.jhep.2019.05.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
6 Brückner M, Heidemann J, Nowacki TM, Cordes F, Stypmann J, Lenz P, Gohar F, Lügering A, Bettenworth D. Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound. World J Gastroenterol 2017; 23(16): 2899-2911 [PMID: 28522908 DOI: 10.3748/wjg.v23.i16.2899] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Ohara H, Isomoto H, Wen CY, Ejima C, Murata M, Miyazaki M, Takeshima F, Mizuta Y, Murata I, Koji T, Nagura H, Kohno S. Expression of mucosal addressin cell adhesion molecule 1 on vessel endothelium of gastric mucosa in patients with nodular gastritis. World J Gastroenterol 2003; 9(12): 2701-2705 [PMID: 14669317 DOI: 10.3748/wjg.v9.i12.2701] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
8 Gabbani T, Deiana S, Marocchi M, Annese V. Genetic risk variants as therapeutic targets for Crohn's disease. Expert Opin Ther Targets 2017;21:381-90. [PMID: 28281904 DOI: 10.1080/14728222.2017.1296431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis 2008;14:1298-312. [PMID: 18393377 DOI: 10.1002/ibd.20453] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
10 Goode D, Aravantinou M, Jarl S, Truong R, Derby N, Guerra-Perez N, Kenney J, Blanchard J, Gettie A, Robbiani M, Martinelli E. Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission. PLoS One 2014;9:e97767. [PMID: 24830732 DOI: 10.1371/journal.pone.0097767] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
11 Kelsen J, Agnholt J, Falborg L, Nielsen JT, Rømer JL, Hoffmann HJ, Dahlerup JF. Indium-labelled human gut-derived T cells from healthy subjects with strong in vitro adhesion to MAdCAM-1 show no detectable homing to the gut in vivo. Clin Exp Immunol 2004;138:66-74. [PMID: 15373907 DOI: 10.1111/j.1365-2249.2004.02578.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
12 Ogawa H, Binion DG, Heidemann J, Theriot M, Fisher PJ, Johnson NA, Otterson MF, Rafiee P. Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am J Physiol Cell Physiol. 2005;288:C272-C281. [PMID: 15483224 DOI: 10.1152/ajpcell.00406.2003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.2] [Reference Citation Analysis]
13 Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, Watanabe K, Hibi T; AJM300 Study Group. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. Gastroenterology 2015;149:1775-1783.e2. [PMID: 26327130 DOI: 10.1053/j.gastro.2015.08.044] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 10.1] [Reference Citation Analysis]
14 Farkas S, Hornung M, Sattler C, Edtinger K, Steinbauer M, Anthuber M, Schlitt HJ, Herfarth H, Geissler EK. Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis. 2006;21:71-78. [PMID: 15856265 DOI: 10.1007/s00384-004-0709-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
15 Allocca M, Fiorino G, Vermeire S, Reinisch W, Cataldi F, Danese S. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Review of Clinical Immunology 2014;10:885-95. [DOI: 10.1586/1744666x.2014.917962] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 Sugiura T, Kageyama S, Andou A, Miyazawa T, Ejima C, Nakayama A, Dohi T, Eda H. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013;7:e533-e542. [PMID: 23623333 DOI: 10.1016/j.crohns.2013.03.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
17 Wendt E, Keshav S. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp Gastroenterol 2015;8:119-30. [PMID: 25897254 DOI: 10.2147/CEG.S48305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
18 Roosenboom B, Lochem EGV, Meijer J, Smids C, Nierkens S, Brand EC, Erp LWV, Kemperman LGJM, Groenen MJM, Horje CSHT, Wahab PJ. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells 2020;9:E891. [PMID: 32268498 DOI: 10.3390/cells9040891] [Reference Citation Analysis]
19 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 de Krijger M, Visseren T, Wildenberg ME, Hooijer GKJ, Verstegen MMA, van der Laan LJW, de Jonge WJ, Verheij J, Ponsioen CY. Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease. J Transl Autoimmun 2020;3:100054. [PMID: 32743534 DOI: 10.1016/j.jtauto.2020.100054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Alagón Fernández Del Campo P, De Orta Pando A, Straface JI, López Vega JR, Toledo Plata D, Niezen Lugo SF, Alvarez Hernández D, Barrientos Fortes T, Gutiérrez-Kobeh L, Solano-Gálvez SG, Vázquez-López R. The Use of Probiotic Therapy to Modulate the Gut Microbiota and Dendritic Cell Responses in Inflammatory Bowel Diseases. Med Sci (Basel) 2019;7:E33. [PMID: 30813381 DOI: 10.3390/medsci7020033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gledhill T, Bodger K. New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biologics. 2013;7:123-130. [PMID: 23723689 DOI: 10.2147/btt.s30416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
23 Pullen N, Molloy E, Carter D, Syntin P, Clemo F, Finco-Kent D, Reagan W, Zhao S, Kawabata T, Sreckovic S. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol. 2009;157:281-293. [PMID: 19366349 DOI: 10.1111/j.1476-5381.2009.00137.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
24 Solano-Gálvez SG, Tovar-Torres SM, Tron-Gómez MS, Weiser-Smeke AE, Álvarez-Hernández DA, Franyuti-Kelly GA, Tapia-Moreno M, Ibarra A, Gutiérrez-Kobeh L, Vázquez-López R. Human Dendritic Cells: Ontogeny and Their Subsets in Health and Disease. Med Sci (Basel) 2018;6:E88. [PMID: 30297662 DOI: 10.3390/medsci6040088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
25 Corso C, Parry JM. Comparative genomic hybridization analysis of N-methyl-N-nitrosoguanidine-induced ratgastrointestinal tumors discloses a cytogenetic fingerprint. Environ Mol Mutagen. 2004;43:20-27. [PMID: 14743342 DOI: 10.1002/em.10211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
26 Di Sabatino A, Rovedatti L, Rosado MM, Carsetti R, Corazza GR, MacDonald TT. Increased expression of mucosal addressin cell adhesion molecule 1 in the duodenum of patients with active celiac disease is associated with depletion of integrin alpha4beta7-positive T cells in blood. Hum Pathol 2009;40:699-704. [PMID: 19157500 DOI: 10.1016/j.humpath.2008.10.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
27 Murphy CT, Nally K, Shanahan F, Melgar S. Shining a light on intestinal traffic. Clin Dev Immunol 2012;2012:808157. [PMID: 22162719 DOI: 10.1155/2012/808157] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
28 Cui Y, Zhu C, Ming Z, Cao J, Yan Y, Zhao P, Pang G, Deng Z, Yao Y, Chen Q. Molecular mechanisms by which casein glycomacropeptide maintains internal homeostasis in mice with experimental ulcerative colitis. PLoS One 2017;12:e0181075. [PMID: 28700735 DOI: 10.1371/journal.pone.0181075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
29 Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol 2017;10:57-66. [PMID: 28424557 DOI: 10.2147/CEG.S110547] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
30 Seguí J, Gil F, Gironella M, Alvarez M, Gimeno M, Coronel P, Closa D, Piqué JM, Panés J. Down-regulation of endothelial adhesion molecules and leukocyte adhesion by treatment with superoxide dismutase is beneficial in chronic immune experimental colitis. Inflamm Bowel Dis. 2005;11:872-882. [PMID: 16189416 DOI: 10.1097/01.MIB.0000183420.25186.7a] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
31 Hibi T, Motoya S, Ashida T, Sai S, Sameshima Y, Nakamura S, Maemoto A, Nii M, Sullivan BA, Gasser RA Jr, Suzuki Y. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res 2019;17:375-86. [PMID: 30739435 DOI: 10.5217/ir.2018.00141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Chandran P, Satthaporn S, Robins A, Eremin O. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (I). Surgeon 2003;1:63-75. [PMID: 15573623 DOI: 10.1016/s1479-666x(03)80118-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wyant T, Fedyk E, Abhyankar B. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. J Crohns Colitis. 2016;10:1437-1444. [PMID: 27252400 DOI: 10.1093/ecco-jcc/jjw092] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 13.5] [Reference Citation Analysis]
34 Raja TW, Veeramuthu D, Savarimuthu I, Al-Dhabi NA. Current Trends in the Treatment of Systemic Lupus Erythematosus. Curr Pharm Des 2020;26:2602-9. [PMID: 32066358 DOI: 10.2174/1381612826666200211122633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
35 Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H. Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol 2015; 6(4): 219-227 [PMID: 26600980 DOI: 10.4291/wjgp.v6.i4.219] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
36 Jin Y, Lin Y, Lin LJ, Zheng CQ. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol 2015; 21(20): 6352-6360 [PMID: 26034371 DOI: 10.3748/wjg.v21.i20.6352] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
37 Chan W, Lynch N, Bampton P, Chang J, Chung A, Florin T, Hetzel DJ, Jakobovits S, Moore G, Pavli P, Radford-Smith G, Thin L, Baraty B, Haifer C, Yau Y, Leong RWL. Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2018;30:735-40. [PMID: 29727386 DOI: 10.1097/MEG.0000000000001150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bernardo D, Vallejo-Díez S, Mann ER, Al-Hassi HO, Martínez-Abad B, Montalvillo E, Tee CT, Murugananthan AU, Núñez H, Peake ST, Hart AL, Fernández-Salazar L, Garrote JA, Arranz E, Knight SC. IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and Tcells they stimulate. Eur J Immunol 2012;42:1337-53. [PMID: 22539302 DOI: 10.1002/eji.201142327] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
39 Staunton DE, Lupher ML, Liddington R, Gallatin WM. Targeting integrin structure and function in disease. Adv Immunol 2006;91:111-57. [PMID: 16938539 DOI: 10.1016/S0065-2776(06)91003-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
40 Mann ER, Landy JD, Bernardo D, Peake ST, Hart AL, Al-Hassi HO, Knight SC. Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men. Immunol Lett. 2013;150:30-40. [PMID: 23352670 DOI: 10.1016/j.imlet.2013.01.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 6.7] [Reference Citation Analysis]
41 Zhang H, Zheng Y, Pan Y, Lin C, Wang S, Yan Z, Lu L, Ge G, Li J, Zeng YA, Chen J. A mutation that blocks integrin α4β7 activation prevents adaptive immune-mediated colitis without increasing susceptibility to innate colitis. BMC Biol 2020;18:64. [PMID: 32522281 DOI: 10.1186/s12915-020-00784-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Suzawa K, Kobayashi M, Sakai Y, Hoshino H, Watanabe M, Harada O, Ohtani H, Fukuda M, Nakayama J. Preferential induction of peripheral lymph node addressin on high endothelial venule-like vessels in the active phase of ulcerative colitis. Am J Gastroenterol. 2007;102:1499-1509. [PMID: 17459027 DOI: 10.1111/j.1572-0241.2007.01189.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
43 Reinisch W, Hung K, Hassan-Zahraee M, Cataldi F. Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1. J Crohns Colitis 2018;12:S669-77. [PMID: 29757363 DOI: 10.1093/ecco-jcc/jjy059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
44 Motaghi E, Hajhashemi V, Mahzouni P, Minaiyan M. The effect of memantine on trinitrobenzene sulfonic acid-induced ulcerative colitis in mice. European Journal of Pharmacology 2016;793:28-34. [DOI: 10.1016/j.ejphar.2016.10.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
45 Hogan SP, Rothenberg ME, Forbes E, Smart VE, Matthaei KI, Foster PS. Chemokines in eosinophil-associated gastrointestinal disorders. Curr Allergy Asthma Rep 2004;4:74-82. [PMID: 14680626 DOI: 10.1007/s11882-004-0047-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
46 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
47 Kozuch PL, Hanauer SB. General Principles and Pharmacology of Biologics in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2006;35:757-73. [DOI: 10.1016/j.gtc.2006.09.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
48 Theodoratou E, Campbell H, Ventham NT, Kolarich D, Pučić-Baković M, Zoldoš V, Fernandes D, Pemberton IK, Rudan I, Kennedy NA, Wuhrer M, Nimmo E, Annese V, McGovern DP, Satsangi J, Lauc G. The role of glycosylation in IBD. Nat Rev Gastroenterol Hepatol 2014;11:588-600. [PMID: 24912389 DOI: 10.1038/nrgastro.2014.78] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 10.3] [Reference Citation Analysis]
49 Saruta M, Papadakis KA. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am 2014;43:581-601. [PMID: 25110260 DOI: 10.1016/j.gtc.2014.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
50 Norman MU, Hickey MJ. Mechanisms of lymphocyte migration in autoimmune disease. Tissue Antigens 2005;66:163-72. [PMID: 16101827 DOI: 10.1111/j.1399-0039.2005.00434.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
51 Gu P, Theiss A, Han J, Feagins LA. Increased Cell Adhesion Molecules, PECAM-1, ICAM-3, or VCAM-1, Predict Increased Risk for Flare in Patients With Quiescent Inflammatory Bowel Disease. J Clin Gastroenterol 2017;51:522-7. [PMID: 27552332 DOI: 10.1097/MCG.0000000000000618] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
52 Ng SC, Kamm MA, Stagg AJ, Knight SC. Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation. Inflamm Bowel Dis 2010;16:1787-807. [PMID: 20222140 DOI: 10.1002/ibd.21247] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
53 Giannoudaki E, Gargan S, Hussey S, Long A, Walsh PT. Opportunities to Target T Cell Trafficking in Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:640497. [PMID: 33816403 DOI: 10.3389/fped.2021.640497] [Reference Citation Analysis]
54 Dotan I, Allez M, Danese S, Keir M, Tole S, McBride J. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. Med Res Rev 2020;40:245-62. [PMID: 31215680 DOI: 10.1002/med.21601] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
55 Rescigno M. Intestinal dendritic cells. Adv Immunol. 2010;107:109-138. [PMID: 21034972 DOI: 10.1016/b978-0-12-381300-8.00004-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
56 Scaldaferri F, Correale C, Gasbarrini A, Danese S. Mucosal biomarkers in inflammatory bowel disease: Key pathogenic players or disease predictors? World J Gastroenterol 2010; 16(21): 2616-2625 [PMID: 20518083 DOI: 10.3748/wjg.v16.i21.2616] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
57 Picardo S, Panaccione R. Anti-MADCAM therapy for ulcerative colitis. Expert Opin Biol Ther 2020;20:437-42. [PMID: 31709847 DOI: 10.1080/14712598.2020.1691520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Lawrance IC. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol 2014; 20(5): 1248-1258 [PMID: 24574799 DOI: 10.3748/wjg.v20.i5.1248] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
59 Jefferson A, Wijesurendra RS, McAteer MA, Choudhury RP. Development and application of endothelium-targeted microparticles for molecular magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012;4:247-56. [PMID: 22407676 DOI: 10.1002/wnan.1164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
60 Zhang YL, Tang ZP. Relationship between mucosal addressin cell adhesion molecule-1 and ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2007; 15(10): 1126-1129 [DOI: 10.11569/wcjd.v15.i10.1126] [Reference Citation Analysis]
61 Cameron S, Schwartz A, Sultan S, Schaefer IM, Hermann R, Rave-Fränk M, Hess CF, Christiansen H, Ramadori G. Radiation-induced damage in different segments of the rat intestine after external beam irradiation of the liver. Exp Mol Pathol 2012;92:243-58. [PMID: 22227376 DOI: 10.1016/j.yexmp.2011.11.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
62 Poole RM. Vedolizumab: first global approval. Drugs 2014;74:1293-303. [PMID: 24985716 DOI: 10.1007/s40265-014-0253-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
63 Biancheri P, Di Sabatino A, Rovedatti L, Giuffrida P, Calarota SA, Vetrano S, Vidali F, Pasini A, Danese S, Corazza GR, Macdonald TT. Effect of Tumor Necrosis Factor-α Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohnʼs Disease: . Inflammatory Bowel Diseases 2013;19:259-64. [DOI: 10.1097/mib.0b013e31828100a4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
64 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol 2014; 20(37): 13234-13238 [PMID: 25309060 DOI: 10.3748/wjg.v20.i37.13234] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
65 Lawrance IC. Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease. Expert Opin Investig Drugs. 2012;21:975-984. [PMID: 22612537 DOI: 10.1517/13543784.2012.690030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
66 Nishida Y, Hosomi S, Watanabe K, Watanabe K, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Yamagami H, Tanigawa T, Watanabe T, Fujiwara Y. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand J Gastroenterol 2018;53:579-85. [PMID: 29171305 DOI: 10.1080/00365521.2017.1403647] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
67 Lamb CA, O'Byrne S, Keir ME, Butcher EC. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. J Crohns Colitis 2018;12:S653-68. [PMID: 29767705 DOI: 10.1093/ecco-jcc/jjy060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
68 Hart AL, Ng SC, Mann E, Al-Hassi HO, Bernardo D, Knight SC. Homing of immune cells: role in homeostasis and intestinal inflammation. Inflamm Bowel Dis. 2010;16:1969-1977. [PMID: 20848507 DOI: 10.1002/ibd.21304] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
69 Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, Mcdonald JW, Cohen A, Bitton A, Baker J, Dubé R, Landau SB, Vandervoort MK, Parikh A. Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin. Clinical Gastroenterology and Hepatology 2008;6:1370-7. [DOI: 10.1016/j.cgh.2008.06.007] [Cited by in Crossref: 203] [Cited by in F6Publishing: 195] [Article Influence: 14.5] [Reference Citation Analysis]
70 Kobayashi M, Hoshino H, Suzawa K, Sakai Y, Nakayama J, Fukuda M. Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases. Semin Immunopathol 2012;34:401-13. [DOI: 10.1007/s00281-012-0302-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
71 Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, Brasier AR, Pinchuk IV, Tian B, Zhou J. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S38-62. [PMID: 34791293 DOI: 10.1093/ibd/izab190] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O’byrne S, Hayday A, Keir ME. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology 2016;150:477-487.e9. [DOI: 10.1053/j.gastro.2015.10.041] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 14.8] [Reference Citation Analysis]
73 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol. 2014;20:13234-13238. [PMID: 25309060 DOI: 10.3748/wjg.v20.i37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Mann ER, Bernardo D, Ng SC, Rigby RJ, Al-Hassi HO, Landy J, Peake ST, Spranger H, English NR, Thomas LV, Stagg AJ, Knight SC, Hart AL. Human gut dendritic cells drive aberrant gut-specific t-cell responses in ulcerative colitis, characterized by increased IL-4 production and loss of IL-22 and IFNγ. Inflamm Bowel Dis 2014;20:2299-307. [PMID: 25397892 DOI: 10.1097/MIB.0000000000000223] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.9] [Reference Citation Analysis]
75 Okanishi H, Kabeya H, Maruyama S, Kagawa Y, Watari T. Activation of nuclear factor-kappa B and cell adhesion molecule mRNA expression in duodenal mucosa of dogs with lymphocytic-plasmacytic enteritis. Veterinary Immunology and Immunopathology 2013;154:145-52. [DOI: 10.1016/j.vetimm.2013.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
76 Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res. 2007;149:173-186. [PMID: 17383591 DOI: 10.1016/j.trsl.2006.11.009] [Cited by in Crossref: 150] [Cited by in F6Publishing: 150] [Article Influence: 10.0] [Reference Citation Analysis]
77 Duchmann R, Zeitz M. Crohn's Disease: Current Pathogenetic Paradigms. Mucosal Immunology. Elsevier; 2005. pp. 1265-85. [DOI: 10.1016/b978-012491543-5/50076-0] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
78 Cao S, Jiang Y, Zhang H, Kondza N, Woodrow KA. Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells. Nanomedicine 2018;14:2143-53. [PMID: 29964219 DOI: 10.1016/j.nano.2018.06.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
79 Kobayashi M, Hoshino H, Masumoto J, Fukushima M, Suzawa K, Kageyama S, Suzuki M, Ohtani H, Fukuda M, Nakayama J. GlcNAc6ST-1-mediated decoration of MAdCAM-1 protein with L-selectin ligand carbohydrates directs disease activity of ulcerative colitis. Inflamm Bowel Dis 2009;15:697-706. [PMID: 19067429 DOI: 10.1002/ibd.20827] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
80 Wiendl M, Becker E, Müller TM, Voskens CJ, Neurath MF, Zundler S. Targeting Immune Cell Trafficking - Insights From Research Models and Implications for Future IBD Therapy. Front Immunol 2021;12:656452. [PMID: 34017333 DOI: 10.3389/fimmu.2021.656452] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:1227-1236. [PMID: 25903741 DOI: 10.1111/apt.13215] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
82 Gabbani T, Deiana S, Annese AL, Lunardi S, Annese V. The genetic burden of inflammatory bowel diseases: implications for the clinic? Expert Rev Gastroenterol Hepatol 2016;10:1109-17. [PMID: 27258545 DOI: 10.1080/17474124.2016.1196131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Villablanca EJ, Cassani B, von Andrian UH, Mora JR. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 2011;140:1776-84. [PMID: 21530744 DOI: 10.1053/j.gastro.2011.02.015] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
84 Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, Rutgeerts P, Vermeire S. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. Clin Gastroenterol Hepatol. 2009;7:972-980.e2. [PMID: 19422935 DOI: 10.1016/j.cgh.2009.05.001] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 8.1] [Reference Citation Analysis]
85 Festen EA, Weersma RK. How will insights from genetics translate to clinical practice in inflammatory bowel disease? Best Pract Res Clin Gastroenterol. 2014;28:387-397. [PMID: 24913379 DOI: 10.1016/j.bpg.2014.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
86 Truffi M, Colombo M, Peñaranda-Avila J, Sorrentino L, Colombo F, Monieri M, Collico V, Zerbi P, Longhi E, Allevi R, Prosperi D, Corsi F. Nano-targeting of mucosal addressin cell adhesion molecule-1 identifies bowel inflammation foci in murine model. Nanomedicine (Lond) 2017;12:1547-60. [PMID: 28621606 DOI: 10.2217/nnm-2017-0004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
87 Zhang YL, Tang ZP, Li K, Dai YC, He XY. Effect of Qingchang Supporsitory on expression of MAdCAM-1 in the colonic mucosa of rats with TNBS-induced colitis. Shijie Huaren Xiaohua Zazhi 2008; 16(30): 3381-3386 [DOI: 10.11569/wcjd.v16.i30.3381] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
88 Mann ER, McCarthy NE, Peake ST, Milestone AN, Al-Hassi HO, Bernardo D, Tee CT, Landy J, Pitcher MC, Cochrane SA, Hart AL, Stagg AJ, Knight SC. Skin- and gut-homing molecules on human circulating γδ T cells and their dysregulation in inflammatory bowel disease. Clin Exp Immunol 2012;170:122-30. [PMID: 23039882 DOI: 10.1111/j.1365-2249.2012.04649.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
89 Mann ER, You J, Horneffer-van der Sluis V, Bernardo D, Omar Al-Hassi H, Landy J, Peake ST, Thomas LV, Tee CT, Lee GH. Dysregulated circulating dendritic cell function in ulcerative colitis is partially restored by probiotic strain Lactobacillus casei Shirota. Mediators Inflamm. 2013;2013:573576. [PMID: 23970814 DOI: 10.1155/2013/573576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
90 Ohya A, Kobayashi M, Sakai Y, Kawashima H, Kageyama S, Nakayama J. Lymphocyte recruitment via high endothelial venules in lymphoid stroma of Warthin's tumour. Pathology 2013;45:150-4. [PMID: 23250041 DOI: 10.1097/PAT.0b013e32835c766d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
91 Zhang LH, Ouyang Q. Expression of MAdCAM-1 and nuclear factor kappa B and the intervention effect of nitric oxide donor in oxazolone-induced colitis. Shijie Huaren Xiaohua Zazhi 2008; 16(6): 596-601 [DOI: 10.11569/wcjd.v16.i6.596] [Reference Citation Analysis]
92 Arriba M, García JL, Rueda D, Pérez J, Brandariz L, Nutu OA, Alonso L, Rodríguez Y, Urioste M, González-Sarmiento R, Perea J. Unsupervised Analysis of Array Comparative Genomic Hybridization Data from Early-Onset Colorectal Cancer Reveals Equivalence with Molecular Classification and Phenotypes. Neoplasia 2017;19:28-34. [PMID: 27987438 DOI: 10.1016/j.neo.2016.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
93 Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest. 2009;119:2441-2450. [PMID: 19729841 DOI: 10.1172/jci39134] [Cited by in Crossref: 209] [Cited by in F6Publishing: 106] [Article Influence: 16.1] [Reference Citation Analysis]
94 Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs 2018;27:623-9. [PMID: 29985060 DOI: 10.1080/13543784.2018.1494722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
95 Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. BioDrugs 2021;35:473-503. [PMID: 34613592 DOI: 10.1007/s40259-021-00496-5] [Reference Citation Analysis]
96 Garlatti V, Lovisa S, Danese S, Vetrano S. The Multiple Faces of Integrin-ECM Interactions in Inflammatory Bowel Disease. Int J Mol Sci 2021;22:10439. [PMID: 34638778 DOI: 10.3390/ijms221910439] [Reference Citation Analysis]
97 Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases. J Crohns Colitis 2020;14:1190-201. [PMID: 32100016 DOI: 10.1093/ecco-jcc/jjaa035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]